Portal de Periódicos da CAPES

Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine

2022; Cell Press; Volume: 185; Issue: 11 Linguagem: Inglês

10.1016/j.cell.2022.04.009

1097-4172

Rishi R. Goel, Mark M. Painter, Kendall A. Lundgreen, Sokratis A. Apostolidis, Amy E. Baxter, Josephine R. Giles, Divij Mathew, Ajinkya Pattekar, Arnold Reynaldi, David S. Khoury, Sigrid Gouma, Philip Hicks, Sarah Dysinger, Amanda Hicks, Harsh Sharma, Sarah Herring, Scott W. Korte, Wumesh KC, Derek A. Oldridge, Rachel I. Erickson, Madison E. Weirick, Christopher M. McAllister, Moses Awofolaju, Nicole Tanenbaum, Jeanette Dougherty, Sherea Long, Kurt D’Andrea, Jacob T. Hamilton, M. A. McLaughlin, Justine C. Williams, Sharon Adamski, Oliva Kuthuru, Elizabeth M. Drapeau, Miles P. Davenport, Scott E. Hensley, Paul Bates, Allison R. Greenplate, E. John Wherry,

CAR-T cell therapy research

Summary We examined antibody and memory B cell responses longitudinally for ∼9–10 months after primary 2-dose SARS-CoV-2 mRNA vaccination and 3 months after a 3rd dose. Antibody decay stabilized between 6 and 9 months, and antibody quality continued to improve for at least 9 months after 2-dose vaccination. Spike- and RBD-specific memory B cells remained durable over time, and 40%–50% of RBD-specific memory B cells simultaneously bound the Alpha, Beta, Delta, and Omicron variants. Omicron-binding memory B cells were efficiently reactivated by a 3rd dose of wild-type vaccine and correlated with the corresponding increase in neutralizing antibody titers. In contrast, pre-3rd dose antibody titers inversely correlated with the fold-change of antibody boosting, suggesting that high levels of circulating antibodies may limit the added protection afforded by repeat short interval boosting. These data provide insight into the quantity and quality of mRNA-vaccine-induced immunity over time through 3 or more antigen exposures.